DWA
DRNA

Dorsey Wright & Associates’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Dorsey Wright & Associates’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,170
Closed -$13K – 344
2018
Q4 		$13K Buy
1,170
+195
+20% +$2.56K ﹤0.01% 238
2018
Q3 		$15K Buy
+975
New +$14.2K ﹤0.01% 226

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dorsey Wright & Associates's DRNA Position: Q1 2019 in Review

Dorsey Wright & Associates sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2019, closing a stake of 1,170 shares — an estimated $13K sold.

Dorsey Wright & Associates first reported a position in DRNA in Q3 2018 and held it in 2 quarters. The position peaked at $15K in Q3 2018. 98 funds tracked by Wall St. Rank hold DRNA as of Q1 2019.

  • Dorsey Wright & Associates reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,170 Dicerna Pharmaceuticals, Inc. shares in Q1 2019, an estimated $13K.
  • Dorsey Wright & Associates first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2018 and held it in 2 quarters.
  • Dorsey Wright & Associates's Dicerna Pharmaceuticals, Inc. position peaked at $15K in Q3 2018.
  • 98 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2019.

Based on Dorsey Wright & Associates's 13F filing for Q1 2019, filed 4 Apr 2019.